Literature DB >> 11603673

Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome.

M Rizzo1, M A Ghert, J M Harrelson, S P Scully.   

Abstract

Chondrosarcoma is the second most common malignant bone tumor and is relatively unresponsive to chemotherapy and radiation regimens. In addition, the clinical course of chondrosarcoma is difficult to predict. The purpose of this study was to review the authors' experience with chondrosarcoma and ascertain any factors related to prognosis and clinical outcome. The medical records of 108 patients followed up for a minimum of 2 years were retrospectively reviewed. There were 31 low-grade and 77 high-grade chondrosarcomas. One hundred one patients underwent surgical resection. There was a statistically significant association between positive margins and local recurrence, metastasis, and death. Tumor grade was not predictive of outcome. Proliferation indices (MIB-1 expression determination through immunohistochemistry) were quantitated in 39 patients. A significant association was seen between MIB-1 expression and recurrence and death. Thus, objective quantitation of tumor proliferation was more predictive than was histologic grade of outcome in chondrosarcoma. Although histologic grade continues to be the standard grading system for chondrosarcoma, the current study contributes to ongoing research and validation of alternative techniques that may be more reliable in guiding prognosis and treatment of chondrosarcoma.

Entities:  

Mesh:

Year:  2001        PMID: 11603673

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  34 in total

1.  Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry.

Authors:  Philipp T Funovics; Joannis Panotopoulos; Manuel Sabeti-Aschraf; Farshid Abdolvahab; Josef M Funovics; Susanna Lang; Rainer I Kotz; Martin Dominkus
Journal:  Int Orthop       Date:  2010-08-28       Impact factor: 3.075

Review 2.  Pathology of primary malignant bone and cartilage tumours.

Authors:  L B Rozeman; A M Cleton-Jansen; P C W Hogendoorn
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

3.  An incidental finding in a young woman (2006: 2b).

Authors:  M Paz Lorente; Carmen De Arriba; Javier Sáenz; Edurne Arteche; Khalil Abu-Shams; Raquel Beloqui
Journal:  Eur Radiol       Date:  2006-03-03       Impact factor: 5.315

4.  Histological grading of primary bone tumors.

Authors:  Edward F McCarthy
Journal:  Skeletal Radiol       Date:  2009-10       Impact factor: 2.199

Review 5.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

6.  Orthopaedic tumors: What problems are we solving, and are universities and major medical centers doing enough?

Authors:  Mohamed Mediouni; Daniel R Schlatterer
Journal:  J Orthop       Date:  2017-05-04

7.  Is there a role for diffusion-weighted MRI (DWI) in the diagnosis of central cartilage tumors?

Authors:  H Douis; L Jeys; R Grimer; S Vaiyapuri; A M Davies
Journal:  Skeletal Radiol       Date:  2015-03-07       Impact factor: 2.199

Review 8.  The clinical management of chondrosarcoma.

Authors:  Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

9.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

10.  Grade I chondrosarcoma of bone: the Münster experience.

Authors:  Arne Streitbürger; Helmut Ahrens; Maurice Balke; Horst Buerger; Winfried Winkelmann; Georg Gosheger; Jendrik Hardes
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.